New research presented at the 2025 International Kidney Cancer Symposium found that patients with localized renal cell ...

Dr. Erika Hamilton spoke with CURE’s editor-in-chief, Dr. Joshua K. Sabari.

Zoldonrasib targets KRAS G12D-mutated non-small cell lung cancer, receiving FDA breakthrough therapy designation for its ...

When I later calculated the financial impact of survivorship, the numbers were staggering: more than $1 million in lost ...

HER2CLIMB-05 trial evaluated Tukysa in combination with Herceptin and Perjeta for HER2-positive metastatic breast cancer, ...

Dave Coulier sat down for an interview with CURE to discuss his recent tongue cancer diagnosis and his treatment journey.

She recently delivered the keynote address at the inaugural Blood Cancer Heroes celebration, held in partnership with Blood ...

From new imaging and targeted therapies to patient journeys, 2025 highlighted key advances and personal stories in lung ...

Colleen Mabasa, a patient with multiple myeloma, discusses her CAR T-cell therapy journey and the pivotal role self-advocacy ...

There are two trials that I think are probably the most excited about. One of them is called the PEAK trial, and it was a ...

The trial met its primary endpoint with a hazard ratio of 0.75, indicating a significant reduction in disease progression ...

Ceremony completes my trio of words. This past year, I've become a vessel for ritual moments that transform ordinary spaces ...